BASEL, Switzerland, October 4 /PRNewswire/ -- Nitec Pharma AG, today announced a substantial expansion of its management team. Nitec appointed Dr. Stephan Witte, as Chief Medical Officer and Head of Global Clinical Development, Dr. Michael Luttgen as Vice President Marketing & Sales, Dr Hans Rensland as Vice President Regulatory Affairs, Dr. Rainer Rogasch as Vice President Technical Operations & Development, Dr. Markus Vogt as Vice President of Quality and Compliance and James Audibert as Vice President Commercial Optimization.
"We are excited to be expanding the Nitec team, with all five candidates having exceptional leadership capabilities and pharmaceutical experience," said Anders Harfstrand the CEO of Nitec. "Their track record in successfully leading companies to the forefront of the industry is outstanding, and we are confident in their abilities to help taking Nitec forward as a successful specialty biopharmaceutical company"
Dr. Stephan Witte, the Chief Medical Officer and Head of Global Clinical Development, has more than 10 years experience in biomedical research and clinical development. Before joining Nitec Pharma, he held a variety of positions with Altana Pharma AG, Quintiles and ICON Clinical Research. His experience includes design and operative management of global clinical development programs and clinical studies in the indications asthma and COPD. Dr. Witte holds a M.S. in Chemistry and completed a PhD thesis at the University of Konstanz. Subsequently he underwent post-doctoral training at the La Jolla Institute for Allergy and Immunology in San Diego and completed post-graduate training in pharmaceutical medicine at the ECPM in Basel.
Dr. Michael Luttgen, Vice President Marketing & Sales at Nitec, held
senior marketing positions in Mayne Pharma, Cephalon and Baxter Germany
during the last four years. At Baxter, he was Marketing Director for Renal
Therapies in Germany. His career in the pharmaceutical industry began at
|SOURCE Nitec Pharma AG|
Copyright©2007 PR Newswire.
All rights reserved